ELANGOVAN BALAKRISHNAN MD NPI 1407843022

NPI Details

Elangovan Balakrishnan, MD is a hematology and oncology internal medicine in Columbia, MO with 25 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Elangovan Balakrishnan, MD NPI is 1407843022. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON
Graduation Year:2001

The provider's business location address is:

1705 E BROADWAY
SUITE 100
COLUMBIA, MO
ZIP 65201-852
Phone: (573) 874-7800
Fax: (573) 443-3627

The NPI 1407843022 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, levoleucovorin, not otherwise specified, 0.5 mg (HCPCS:J0641)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, bendamustine hcl (bendeka), 1 mg (HCPCS:J9034)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Ct scan of chest with contrast (HCPCS:71260)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection of drug or substance into vein (HCPCS:96374)
• Ct scan of chest without contrast (HCPCS:71250)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev (HCPCS:G6012)
• Injection, midazolam hydrochloride, per 1 mg (HCPCS:J2250)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Hospital discharge day management, 30 minutes or less (HCPCS:99238)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free (HCPCS:90674)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Drawing of blood for a medical problem (HCPCS:99195)
• Continuing radiation therapy consultation per week (HCPCS:77336)
• X-ray of chest, 2 views (HCPCS:71046)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Nuclear medicine study whole body with ct scan (HCPCS:78816)

The enumeration date for this NPI number is 9/29/2005 and was last updated on 1/30/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.